Recent News

• 01.16.2026 - Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 01.12.2026 - Xenon Outlines Key Upcoming Milestones at the 2026 J.P. Morgan Healthcare Conference
• 01.05.2026 - Xenon to Present at the 44th Annual J.P. Morgan Healthcare Conference
• 12.05.2025 - Xenon Showcases New 48-Month Azetukalner OLE Study Data in Epilepsy at AES 2025
• 12.04.2025 - Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 12.03.2025 - Xenon Announces Investor Webinar Highlighting Azetukalner and Epilepsy Data from AES 2025
• 11.25.2025 - Xenon to Present New Azetukalner OLE Study Data in Epilepsy at AES 2025

Recent Filings

• 01.09.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.09.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.09.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.09.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.02.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.02.2026 - 144 Report of proposed sale of securities
• 12.09.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.08.2025 - 144 Report of proposed sale of securities
• 12.05.2025 - 144 Report of proposed sale of securities
• 12.03.2025 - 4 Statement of changes in beneficial ownership of securities